Acifran: HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran, chemically (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a validated selective agonist for the HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) receptors, both G-protein coupled receptors involved in lipid metabolism regulation (Ye et al., 2025). The compound's efficacy and specificity were recently confirmed via cryo-EM structures at 2.72–3.18 Å resolution, directly visualizing its interaction with the binding pockets of human HCAR2 and HCAR3. Acifran exhibits a molecular weight of 218.21 g/mol, solubility below 21.82 mg/ml in ethanol and DMSO, and a purity of 98.00% (APExBIO product page). The compound is used exclusively for research, notably in studies of lipid signaling pathways and metabolic disorder mechanisms. Its stability profile requires storage at –20°C and prompt solution use to maintain activity.

Biological Rationale

Lipid metabolism is regulated by a network of G-protein coupled receptors (GPCRs), among which HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) play central roles in sensing endogenous hydroxycarboxylic acids. These receptors are implicated in the modulation of plasma lipid levels and represent therapeutic targets for dyslipidemia and metabolic disorders (Ye et al., 2025). Activation of HCAR2 by agonists such as niacin is clinically established to reduce plasma triglycerides and increase HDL cholesterol; however, HCAR3's distinct ligand recognition profile may enable similar lipid-modulating effects without certain adverse side effects. Structural and functional delineation of these receptors is critical for designing next-generation hypolipidemic agents. Acifran's selectivity and well-characterized binding provide a robust tool for dissecting lipid signaling pathways at the molecular and cellular level (related article—this article extends the mechanistic focus by direct structural evidence).

Mechanism of Action of Acifran

Acifran functions as a selective agonist of HCAR2 and HCAR3, both of which are GPCRs. Upon binding to the orthosteric site of these receptors, Acifran induces conformational changes that promote coupling to Gi proteins. This in turn inhibits adenylyl cyclase activity, leading to reduced intracellular cAMP levels and downstream modulation of lipid metabolic pathways (Ye et al., 2025). Recent cryo-EM studies have visualized Acifran's binding mode within HCAR3 and HCAR2, confirming π–π stacking with F1073.32 in HCAR3 and highlighting size differences in the ligand pocket that underlie receptor selectivity. These insights allow for targeted manipulation of lipid metabolism with minimized off-target effects (related article—our article details the structural mechanism with recent cryo-EM data).

Evidence & Benchmarks

• Acifran forms a stable complex with HCAR3-Gi, resolved by cryo-EM at 3.18 Å (Ye et al., 2025, DOI).
• The Acifran-HCAR2-Gi1-scFv16 complex was resolved at 2.72 Å, confirming direct orthosteric site engagement (Ye et al., 2025, DOI).
• In HEK-293 cell cAMP assays, Acifran displays selective activation of HCAR2 and HCAR3, with minimal cross-reactivity to other GPCRs (Ye et al., 2025, DOI).
• Acifran's chemical purity is ≥98.00% by HPLC, as shipped by APExBIO (product page).
• Stability is maintained when stored at –20°C and protected from repeated freeze-thaw cycles (APExBIO data).
• Ligand-receptor selectivity is determined by π–π interactions at F1073.32 (HCAR3) and pocket residue differences, as shown in atomic models deposited under PDB 9JKX/9JKY (PDB 9JKX).

Applications, Limits & Misconceptions

Acifran is widely used for:

• Dissecting lipid signaling pathway dynamics in vitro and in cell-based assays.
• Benchmarking selective activation of HCAR2 and HCAR3 in metabolic disorder models.
• Optimizing screening workflows for hypolipidemic drug discovery (related article—this article provides deeper structural interpretation).
• Developing mechanistic hypotheses for avoiding HCAR2-mediated adverse effects, such as cutaneous flushing, by exploiting HCAR3 selectivity.

Common Pitfalls or Misconceptions

• Not a therapeutic agent: Acifran is intended strictly for research and is not approved for diagnostic or clinical use (APExBIO).
• Solution stability: Prepared solutions are not recommended for long-term storage; activity may decrease after repeated freeze-thaw cycles.
• Non-specific GPCR effects: At excessive concentrations, off-target GPCR activation may occur; always titrate to recommended levels as per published protocols (Ye et al., 2025).
• Species cross-reactivity: Receptor selectivity and downstream effects may differ across species; verify target homology before in vivo application.
• Solvent compatibility: Solubility is <21.82 mg/ml in ethanol and DMSO; ensure complete dissolution before experimental use.

Workflow Integration & Parameters

Acifran (SKU B6848) is supplied as an off-white solid, shipped with blue ice, and should be stored at –20°C upon receipt (APExBIO product page). For experimental use, dissolve in ethanol or DMSO to a maximum concentration of 21.82 mg/ml. Immediate use of freshly prepared solutions is recommended to maintain agonist activity. In cell-based assays, Acifran is typically used at micromolar concentrations; users should refer to dose-response data as benchmarked in HEK-293 cAMP experiments (Ye et al., 2025). The compound is compatible with a variety of lipid metabolism models and can be integrated into receptor activation, downstream signaling, and cytotoxicity assays. For troubleshooting, refer to scenario-driven guidance such as in "Acifran (SKU B6848): Data-Driven Solutions for Lipid Metabolism"—this article clarifies recent structural and purity standards.

Conclusion & Outlook

Acifran is a rigorously validated tool compound for lipid metabolism and metabolic disorder research. Its structural mechanism of action, selectivity, and high purity as provided by APExBIO support its widespread use in GPCR signaling studies. Future advances in receptor-specific drug discovery are expected to build on the molecular benchmarks established by Acifran (Ye et al., 2025). For in-depth structural and translational context, see "Acifran and the Future of Lipid Metabolism Research"—this article updates and extends prior reviews with direct cryo-EM and workflow data.